ImmusanT Discontinues Phase 2 Clinical Trial for Nexvax2® in Patients With Celiac Disease
June 25, 2019 14:01 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., June 25, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT to Present at the Jefferies 2019 Healthcare Conference
May 29, 2019 10:17 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., May 29, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT Presents Early Evidence Supporting its Lead Therapeutic Vaccine Candidate During the Digestive Disease Week Annual Conference 2019
May 21, 2019 12:12 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., May 21, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT to Present New Findings on Celiac Disease and Lead Therapeutic Candidate During the Digestive Disease Week Annual Conference 2019
May 16, 2019 10:35 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., May 16, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT to Present and Participate in Multiple Upcoming Industry and Scientific Conferences
March 21, 2019 13:00 ET
|
ImmusanT, Inc.
ImmusanT CEO Leslie Williams to speak on panel during the MassBio Annual “The State of Possible Conference” ImmusanT CSO Dr. Bob Anderson to present on Nexvax2 at the 2nd Antigen Specific Immune...
ImmusanT to Provide Corporate Overview at the Cowen & Company 39th Annual Health Care Conference
March 06, 2019 08:00 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., March 06, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT Expands Senior Management Team with Appointment of Thomas A. Shea as Chief Financial Officer
January 03, 2019 09:47 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., Jan. 03, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT Secures Fast-Track Designation for Lead Therapeutic Vaccine Candidate Nexvax2 for Patients with Celiac Disease (CeD)
January 02, 2019 10:17 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical-stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT Chief Scientific Officer Robert Anderson, Ph.D. to Participate as a Featured Speaker During the Antigen-Specific Immune Tolerance Europe Conference 2018
December 07, 2018 12:53 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., Dec. 07, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...
ImmusanT CEO Leslie Williams to Present at Multiple Life Sciences Events to Share Company’s Leadership Position in the Industry and Successful Growth Strategy
November 20, 2018 09:30 ET
|
ImmusanT, Inc.
CAMBRIDGE, Mass., Nov. 20, 2018 (GLOBE NEWSWIRE) -- ImmusanT, Inc., a clinical stage company leveraging its Epitope-Specific Immuno-Therapy™ (ESIT™) platform to deliver first-in-class peptide-based...